Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 5 de 5
Filtrar
Mais filtros








Base de dados
Intervalo de ano de publicação
1.
Neurochem Res ; 34(8): 1427-32, 2009 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-19259810

RESUMO

A case-control study was undertaken to investigate the status of platelet monoamine oxidase-B (MAO-B) activity in Indian cases of idiopathic Parkinson's disease. A significant increase in the activity of platelet MAO-B was observed in Parkinson's cases (n = 26) as compared to controls (n = 26). No significant change in the activity of the enzyme was observed while the data was analysed with respect to age, sex and duration of disease. A trend of decrease in platelet MAO-B activity was observed in Parkinson's cases with respect to stage although the change was not significant. No correlation in platelet MAO-B activity was observed with respect to age and sex in the control subjects. Parkinson's cases treated with L-DOPA and MAO-B inhibitor exhibited decreased platelet MAO-B activity as compared to drug naive cases and those treated with L-DOPA alone. Interestingly, Parkinson's cases treated with L-DOPA and amantadine also had lower platelet MAO-B activity as compared to drug naive cases and those treated with L-DOPA alone. Activity of platelet MAO-B in Parkinson's patients was increased in naive cases and those treated with L-DOPA alone or in combination with other drugs compared to controls. The results of the present study indicate that phenotypic activity of platelet MAO-B is high in Indian Parkinson's cases. Further, action mechanism of drugs used in the treatment of Parkinson's disease could be understood by assay of platelet MAO-B activity. It is an interesting observation and may be looked further in large number of cases.


Assuntos
Plaquetas/enzimologia , Monoaminoxidase/sangue , Doença de Parkinson/sangue , Doença de Parkinson/enzimologia , Adulto , Idoso , Amantadina/uso terapêutico , Antiparkinsonianos/uso terapêutico , Progressão da Doença , Feminino , Humanos , Índia , Levodopa/uso terapêutico , Masculino , Pessoa de Meia-Idade , Doença de Parkinson/tratamento farmacológico , Adulto Jovem
2.
Neurochem Res ; 33(6): 1036-43, 2008 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-18204970

RESUMO

Turmeric has been in use since ancient times as a condiment and due to its medicinal properties. Curcumin, the yellow colouring principle in turmeric, is polyphenolic and major active constituent. Besides anti-inflammatory, thrombolytic and anticarcinogenic activities, curcumin also possesses strong antioxidant property. In view of the novel combination of properties, neuroprotective efficacy of curcumin was studied in rat middle cerebral artery occlusion (MCAO) model. Rats were subjected to 2 h of focal ischemia followed by 72 h of reperfusion. They were pre-treated with curcumin (100 mg/kg, po) for 5 days prior to MCAO and for another 3 days after MCAO. The parameters studied were behavioural, biochemical and histological. Treatment with curcumin could significantly improve neurobehavioral performance compared to untreated ischemic rats as judged by its effect on rota-rod performance and grid walking. A significant inhibition in lipid peroxidation and an increase in superoxide dismutase (SOD) activity in corpus striatum and cerebral cortex was observed following treatment with curcumin in MCAO rats as compared to MCAO group. Intracellular calcium levels were decreased following treatment with curcumin in MCAO rats. Histologically, a reduction in the infarct area from 33% to 24% was observed in MCAO rats treated with curcumin. The study demonstrates the protective efficacy of curcumin in rat MCAO model.


Assuntos
Isquemia Encefálica , Encéfalo/efeitos dos fármacos , Curcumina/farmacologia , Fármacos Neuroprotetores/farmacologia , Animais , Comportamento Animal/efeitos dos fármacos , Encéfalo/anatomia & histologia , Isquemia Encefálica/metabolismo , Isquemia Encefálica/prevenção & controle , Cálcio/metabolismo , Inibidores Enzimáticos/farmacologia , Humanos , Infarto da Artéria Cerebral Média , Peroxidação de Lipídeos , Masculino , Ratos , Ratos Wistar , Superóxido Dismutase/metabolismo
3.
Hum Exp Toxicol ; 25(4): 187-94, 2006 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-16696294

RESUMO

The neuroprotective potential of ethanol:water (1:1) extract of rhizomes of Acorus calamus (AC-002) has been investigated in middle cerebral artery occlusion (MCAO)-induced ischaemia in rats. A significant behavioural impairment in Rota-Rod performance and grid walking was observed in rats, 72 hours after MCAO as compared to sham-operated animals. These rats also exhibited an increase in lipid peroxidation (cortex -157%, corpus striatum - 58%) and a decrease in glutathione levels (cortex - 59%, corpus striatum - 34%) and superoxide dismutase (SOD) activity (cortex - 64%, corpus striatum - 32%) as compared to sham-operated animals. Ischaemic rats treated with AC-002 (25 mg/kg, p.o.) exhibited a significant improvement in neurobehavioural performance viz. Rota-Rod performance and grid walking as compared to the MCAO group. Interestingly, treatment with AC-002 in MCAO rats significantly decreased malonaldialdehyde levels in cortex as compared to ischaemic rats. A significant increase in reduced glutathione levels and SOD activity was also observed both in cortex and corpus striatum in MCAO rats treated with AC-002 in comparison to MCAO rats. Treatment with AC-002 in MCAO rats also reduced the contralateral cortical infarct area (19%) as compared to MCAO rats (33%). Neurological function score was improved in the AC-002-treated rats as compared to the MCAO group. The results of the present study indicate the neuroprotective efficacy of A. calamus in the rat model of ischaemia.


Assuntos
Acorus/química , Isquemia Encefálica/tratamento farmacológico , Artéria Cerebral Média , Fármacos Neuroprotetores/uso terapêutico , Animais , Peso Corporal/efeitos dos fármacos , Isquemia Encefálica/patologia , Glutationa/metabolismo , Peroxidação de Lipídeos/efeitos dos fármacos , Masculino , Proteínas do Tecido Nervoso/metabolismo , Oxirredução , Extratos Vegetais/uso terapêutico , Raízes de Plantas/química , Equilíbrio Postural/efeitos dos fármacos , Desempenho Psicomotor/efeitos dos fármacos , Ratos , Ratos Wistar , Superóxido Dismutase/metabolismo
4.
Life Sci ; 78(18): 2081-7, 2006 Mar 27.
Artigo em Inglês | MEDLINE | ID: mdl-16413584

RESUMO

Turmeric (Curcuma longa rhizomes), commonly used as a spice is well documented for its medicinal properties in Indian and Chinese systems of medicine. It has been widely used for the treatment of several diseases. Epidemiological observations, though inconclusive, are suggestive that turmeric consumption may reduce the risk of some form of cancers and render other protective biological effects in humans. These biological effects of turmeric have been attributed to its constituent curcumin that has been widely studied for its anti-inflammatory, anti-angiogenic, anti-oxidant, wound healing and anti-cancer effects. As a result of extensive epidemiological, clinical, and animal studies several molecular mechanisms are emerging that elucidate multiple biological effects of curcumin. This review summarizes the most interesting in vitro and in vivo studies on the biological effects of curcumin.


Assuntos
Antineoplásicos Fitogênicos/farmacologia , Curcumina/farmacologia , Inibidores da Angiogênese/farmacologia , Animais , Anticarcinógenos , Antineoplásicos Fitogênicos/química , Antioxidantes/farmacologia , Curcumina/química , Humanos , Neovascularização Patológica/prevenção & controle , Cicatrização/efeitos dos fármacos
5.
Hum Exp Toxicol ; 22(12): 653-8, 2003 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-14992327

RESUMO

Curcumin (diferuloylmethane), an active ingredient of turmeric, is known to have multiple activities, including an antioxidant property, and has been suggested to be of use in treatment of several diseases. The present study has been undertaken to investigate the protective effect of curcumin against lead-induced neurotoxicity in rats. Exposure of rats to lead (50 mg/kg po) for 45 days caused an increase in lipid peroxidation (LPO) and a decrease in reduced glutathione (GSH) levels in cerebellum, corpus striatum, hippocampus and frontal cortex as compared with controls. Lead levels were significantly increased in these rats. Activity of antioxidant enzymes superoxide dismutase (SOD) and catalase (CAT) decreased in all the brain regions following lead exposure. Interestingly, cotreatment with curcumin (100 mg/kg po) and lead (50 mg/kg po) for 45 days caused a significant decrease in LPO with concomitant decrease in lead levels in all the brain regions as compared with those treated with lead alone. A significant increase in reduced glutathione (GSH) levels, SOD and CAT activities was also observed in all the four brain regions in rats simultaneously treated with curcumin and lead. The results suggest that curcumin may prevent lead-induced neurotoxicity.


Assuntos
Curcumina/uso terapêutico , Síndromes Neurotóxicas/tratamento farmacológico , Compostos Organometálicos/efeitos adversos , Compostos Organometálicos/antagonistas & inibidores , Administração Oral , Animais , Catalase/antagonistas & inibidores , Catalase/química , Cerebelo/química , Cerebelo/efeitos dos fármacos , Corpo Estriado/efeitos dos fármacos , Corpo Estriado/enzimologia , Corpo Estriado/metabolismo , Curcumina/administração & dosagem , Curcumina/farmacocinética , Esquema de Medicação , Glutationa/antagonistas & inibidores , Glutationa/efeitos dos fármacos , Hipocampo/efeitos dos fármacos , Hipocampo/enzimologia , Hipocampo/metabolismo , Peroxidação de Lipídeos/efeitos dos fármacos , Peroxidação de Lipídeos/fisiologia , Masculino , Córtex Motor/efeitos dos fármacos , Córtex Motor/enzimologia , Córtex Motor/metabolismo , Compostos Organometálicos/farmacocinética , Ratos , Ratos Wistar , Superóxido Dismutase/antagonistas & inibidores , Superóxido Dismutase/química , Substâncias Reativas com Ácido Tiobarbitúrico/análise , Fatores de Tempo , Distribuição Tecidual
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA